AR100169A1 - Tratamiento del cáncer - Google Patents
Tratamiento del cáncerInfo
- Publication number
- AR100169A1 AR100169A1 ARP150101225A ARP150101225A AR100169A1 AR 100169 A1 AR100169 A1 AR 100169A1 AR P150101225 A ARP150101225 A AR P150101225A AR P150101225 A ARP150101225 A AR P150101225A AR 100169 A1 AR100169 A1 AR 100169A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- tumor
- cancer treatment
- expression levels
- positive cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 abstract 4
- 102100025136 Macrosialin Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 abstract 1
- 229960003005 axitinib Drugs 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000003364 immunohistochemistry Methods 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983951P | 2014-04-24 | 2014-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100169A1 true AR100169A1 (es) | 2016-09-14 |
Family
ID=53398149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101225A AR100169A1 (es) | 2014-04-24 | 2015-04-23 | Tratamiento del cáncer |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20170184602A1 (enExample) |
| EP (1) | EP3134119B1 (enExample) |
| JP (1) | JP6603474B2 (enExample) |
| KR (1) | KR101943177B1 (enExample) |
| CN (1) | CN106233143B (enExample) |
| AR (1) | AR100169A1 (enExample) |
| AU (3) | AU2015249513A1 (enExample) |
| BR (1) | BR112016024143A2 (enExample) |
| CA (1) | CA2946362C (enExample) |
| CY (1) | CY1120731T1 (enExample) |
| DK (1) | DK3134119T3 (enExample) |
| ES (1) | ES2691213T3 (enExample) |
| HU (1) | HUE040167T2 (enExample) |
| IL (1) | IL247859B (enExample) |
| MX (1) | MX375794B (enExample) |
| PL (1) | PL3134119T3 (enExample) |
| PT (1) | PT3134119T (enExample) |
| RU (1) | RU2651469C1 (enExample) |
| SG (1) | SG11201607918TA (enExample) |
| SI (1) | SI3134119T1 (enExample) |
| TR (1) | TR201815682T4 (enExample) |
| TW (1) | TWI568439B (enExample) |
| WO (1) | WO2015162532A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6945199B2 (ja) | 2017-05-19 | 2021-10-06 | 国立大学法人山口大学 | アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法 |
| EP3820520A4 (en) | 2018-07-12 | 2022-05-11 | Corvus Pharmaceuticals, Inc. | METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY |
| JP2021532084A (ja) | 2018-07-12 | 2021-11-25 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシン経路活性化を有する癌を検出および治療するための方法 |
| US10586164B1 (en) | 2018-10-15 | 2020-03-10 | AIble Inc. | Interface for visualizing and improving model performance |
| US10936768B2 (en) * | 2018-10-15 | 2021-03-02 | Aible, Inc. | Interface for visualizing and improving model performance |
| WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| CA3252723A1 (en) * | 2022-05-11 | 2023-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | USE OF A REP PROTEIN BMMF1 AS A DIAGNOSTIC MARKER FOR LUNG CANCER |
| CA3252712A1 (en) * | 2022-05-11 | 2023-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | USE OF REP BMMF1 PROTEIN AS A DIAGNOSTIC MARKER FOR PANCREATIC CANCER AND TYPE 2 DIABETES |
| WO2024026407A1 (en) * | 2022-07-28 | 2024-02-01 | The Board Of Regents Of The University Of Oklahoma | Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1678327A4 (en) | 2003-10-16 | 2007-10-10 | Genomic Health Inc | QRT-PCR TEST SYSTEM FOR GENE EXPRESSION PROFILING |
| EP2947160B1 (en) * | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| CA2626019A1 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| WO2008013912A1 (en) * | 2006-07-28 | 2008-01-31 | Novartis Ag | Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma |
| WO2008066755A2 (en) * | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
| WO2011003911A1 (en) * | 2009-07-08 | 2011-01-13 | Vladimir Lazar | Method for predicting efficacy of drugs in a patient |
| WO2011033006A1 (en) * | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| US7736861B1 (en) * | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| WO2012068487A1 (en) * | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
| US9046534B2 (en) * | 2011-10-04 | 2015-06-02 | Invivis Pharmaceuticals Inc. | Methods and systems for identifying and treating anti-progestin sensitive tumors |
| MX356802B (es) | 2012-01-13 | 2018-06-13 | Genentech Inc | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. |
-
2015
- 2015-04-16 SI SI201530426T patent/SI3134119T1/sl unknown
- 2015-04-16 ES ES15729222.8T patent/ES2691213T3/es active Active
- 2015-04-16 SG SG11201607918TA patent/SG11201607918TA/en unknown
- 2015-04-16 WO PCT/IB2015/052796 patent/WO2015162532A1/en not_active Ceased
- 2015-04-16 US US15/305,066 patent/US20170184602A1/en not_active Abandoned
- 2015-04-16 AU AU2015249513A patent/AU2015249513A1/en not_active Abandoned
- 2015-04-16 HU HUE15729222A patent/HUE040167T2/hu unknown
- 2015-04-16 BR BR112016024143A patent/BR112016024143A2/pt not_active Application Discontinuation
- 2015-04-16 PT PT15729222T patent/PT3134119T/pt unknown
- 2015-04-16 MX MX2016013910A patent/MX375794B/es active IP Right Grant
- 2015-04-16 TR TR2018/15682T patent/TR201815682T4/tr unknown
- 2015-04-16 KR KR1020167029131A patent/KR101943177B1/ko not_active Expired - Fee Related
- 2015-04-16 CA CA2946362A patent/CA2946362C/en not_active Expired - Fee Related
- 2015-04-16 RU RU2016140271A patent/RU2651469C1/ru active
- 2015-04-16 EP EP15729222.8A patent/EP3134119B1/en not_active Not-in-force
- 2015-04-16 CN CN201580021401.8A patent/CN106233143B/zh not_active Expired - Fee Related
- 2015-04-16 DK DK15729222.8T patent/DK3134119T3/en active
- 2015-04-16 PL PL15729222T patent/PL3134119T3/pl unknown
- 2015-04-22 JP JP2015087291A patent/JP6603474B2/ja not_active Expired - Fee Related
- 2015-04-23 TW TW104113043A patent/TWI568439B/zh not_active IP Right Cessation
- 2015-04-23 AR ARP150101225A patent/AR100169A1/es unknown
-
2016
- 2016-09-16 IL IL247859A patent/IL247859B/en active IP Right Grant
-
2018
- 2018-05-03 AU AU2018203086A patent/AU2018203086A1/en not_active Abandoned
- 2018-10-05 CY CY181101033T patent/CY1120731T1/el unknown
-
2019
- 2019-03-01 US US16/290,827 patent/US20190331687A1/en not_active Abandoned
-
2020
- 2020-01-13 AU AU2020200237A patent/AU2020200237A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100169A1 (es) | Tratamiento del cáncer | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| CY1124879T1 (el) | Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου | |
| MX2025002382A (es) | Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX391229B (es) | Metodos de tratamiento de neoplasias malignas. | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| UY36325A (es) | Paneles del gen mutante del fgfr para identificar cánceres sensibles al tratamiento con un inhibidor del fgfr | |
| AR101765A1 (es) | Agentes de unión al cd123 y usos de estos | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2016012697A (es) | Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales. | |
| MX2016012176A (es) | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
| MX2015014486A (es) | Marcadores de respuesta de células tumorales a la terapia. | |
| MX356802B (es) | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. | |
| MX394474B (es) | Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo. | |
| CY1124191T1 (el) | Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις | |
| MX2018009254A (es) | Metodos para evaluar el riesgo de desarrollar cancer colorrectal. | |
| BR112016016635A2 (pt) | Método e aparelho para isolar células invasivas e metastáticas para avaliação terapêutica e previsão de capacidade metastática | |
| MX392040B (es) | Estandares de antigeno prostatico y sus usos. | |
| IL316167A (en) | Methods for diagnosing and treating patients with cutaneous squamous cell carcinoma | |
| SV2017005459A (es) | Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| EP3596467C0 (en) | DETECTION, QUANTIFICATION AND/OR ISOLATION OF CIRCULATING TUMOR CELLS BASED ON THE EXPRESSION OF THE CD321 MARKER | |
| JOP20190067A1 (ar) | طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |